It is often challenging to accurately predict human in vivo clearance from in vitro intrinsic clearance data for poorly metabolised compounds. To address this issue, Cyprotex's parent company, Evotec, have developed a low clearance human hepatocyte stability assay. The method, which uses plated human hepatocytes and a gel overlay, evaluates intrinsic clearance over extended time periods. Using this approach the extrapolation from in vitro to in vivo human intrinsic clearance is significantly improved compared to standard short term suspension methods. You can find out more below.
An article has recently been published in ATLA which details insight into a new collaboration known as the Alliance for Human Relevant Science. Cyprotex are founding members of the Alliance and are committed to the development and promotion of human relevant methods in order to reduce reliance on animal testing. Find out how you can download the publication for free.
In May, Cyprotex scientists attended the NC3Rs/SPS regional meeting in the UK and presented a poster on our 3D organ-specific research in the area of cardiotoxicity, nephrotoxicity and DILI. Download the poster below.
From 26-29 June, Cyprotex will be exhibiting and presenting posters at the ISSX conference in Cologne. Arrange a meeting with one of our scientists at the event.
Finally, in December last year, Cyprotex became part of the Evotec Group. We would like to share with you some of the highlights from the Evotec Group as whole.